Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Recurrent or Metastatic Endometrial Carcinoma
NCT00478426Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2007
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in endometrial carcinoma, sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate up to 7 years. Started Apr 2007; status: completed.
02
Drugs
sunitinib
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT00478426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00478426.